Celgene, Google double down on Armo’s PhIII immuno-oncology drug with $67M round
Armo BioSciences has lined up a big $67 million C round to pay for the late-stage development of some of its immuno-oncology assets. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
